Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Background:

• Oligomeric amyloid-beta (Aβ) 1-42 is known to impair synaptic function in early Alzheimer's disease (AD).
• N-terminally truncated Aβ forms are abundant posttranslational modifications, but their independent synaptotoxic mechanisms remain unclear.

Purpose of the Study:

• To investigate whether modified Aβ species, specifically pyroglutamated Aβ3(pE)-42, can induce synaptic dysfunction independently.
• To elucidate the distinct biochemical properties and synaptotoxic mechanisms of Aβ3(pE)-42 compared to Aβ1-42.

Main Methods:

• Comparative analysis of synaptic dysfunction induced by Aβ1-42 and Aβ3(pE)-42.
• Investigation of Aβ3(pE)-42 interaction with synaptic membranes and prion protein.
• Assessment of astrocyte uptake and cytokine release (TNFα) induced by Aβ3(pE)-42.
• Evaluation of the role of NMDAR signaling and D1-agonists in Aβ3(pE)-42-induced synaptic impairment.

Main Results:

• Aβ3(pE)-42 induces synaptic dysfunction comparable to Aβ1-42 but through different pathways.
• Unlike Aβ1-42, Aβ3(pE)-42 is internalized by astrocytes, triggering the release of pro-inflammatory TNFα.
• Aβ3(pE)-42-induced synaptic dysfunction is independent of NMDAR signaling and not rescued by D1-agonists.

Conclusions:

• Post-translationally modified soluble oligomeric Aβ, like Aβ3(pE)-42, contributes to synaptic dysfunction in AD.
• Neuroinflammatory processes mediated by astrocytes and direct synaptotoxic effects of modified Aβ act synergistically in AD pathogenesis.
• Understanding these distinct mechanisms is crucial for developing targeted AD therapies.